WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

2 October 2017

TiGenix to host Analyst and Investor Event in New York City (ENNLFRES)

28 September 2017

TiGenix to participate and present at key investor and business development meetings (EN – NLFRES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
23.30 USD
Change (%):
-0.79 (-3.28%)
BRU
1.02 EUR
Change (%):
-0.02 (-1.55%)